Feb. 1, 2008 | Vol. 2 No. 5
Stryker is voluntarily recalling certain implants manufactured at its Cork, Ireland, facility after discovering a deviation from its internal specifications.
Unsanitary manufacturing conditions at Amico Laboratories were cited in a recent FDA warning letter.
Bristol-Myers Squibb’s (BMS) new $1.5 billion productivity initiative targets $400 million in expense reductions derived from savings and cost avoidance in its manufacturing operations.
For months, people around Terre Haute hoped Pfizer would move a new product line into its massive factory just south of town to help fill the loss after the company pulled the plug on its Exubera inhaled insulin line in October.
Oakwood Laboratories LLC has agreed to produce an injectible drug meant to fight alcohol dependence for German pharmaceutical company elbion NV.
Israel’s Teva Pharmaceutical Industries, one of the world’s largest generics makers, may double its capacity in its Hungarian plant in a $100 million investment that would create Europe’s largest pharmaceutical production unit, business daily Világgazdaság reported.
Shasun Chemicals & Drugs Ltd. has announced that it is setting up a process development facility in Piscataway (New Jersey), U.S.
Small and medium enterprises (SMEs) in the pharma sector can look forward to a better future as many companies are likely to source raw materials from the domestic market due to spiraling costs of imports from China.
SAFC, a member of the Sigma-Aldrich Group, has announced the second-phase of a $600,000 expansion of its solid-state services Pharmorphix research facility in Cambridge, UK, adding 7,500 sq. ft. of laboratory capacity to support this fast growing business within its SAFC Pharma focus area.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.